News
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
In the past year or couple of years, you’ve likely heard a lot about Ozempic, most likely in the context of weight loss. Not ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in ...
Ozempic, chemically known as semaglutide, is now the first approved treatment in Canada for type 2 diabetes and to slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback